CategorySurgical robots
Overview
Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
Valuation of record
Company-claimedPriced roundSeries D post-money
Key facts
CEO
Form factor
FDA status
CE Mark
Founded
Stage
Product
FDA pathway
Data & sources
Web sources
4
4 sources backing this record.View all →
Models (1)
View all models →Current leadership (1)
- Steve Augustine CEOreported, not verified
Safety record
No incidents on record for HistoSonics.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
HistoSonics in third-party press
Funding rounds (1)
- Series D2026-06-22
$102M · $3.8B post
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 23, 2026
Added to the verified registry
Sources (4)
Common questions
- What is HistoSonics?
- Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.
- What does HistoSonics make?
- HistoSonics has 1 robot model on the DEPLOY registry: Edison Histotripsy System (HistoSonics builds physical robots).
- Who is the CEO of HistoSonics?
- Steve Augustine is the ceo of HistoSonics, per the DEPLOY registry.
- Where is HistoSonics headquartered?
- HistoSonics is headquartered in Plymouth, MN, USA.
- Where does HistoSonics operate robots?
- HistoSonics is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- When was HistoSonics founded?
- HistoSonics was founded in 2009.
- Is HistoSonics safe?
- HistoSonics has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 4 sources (no primary) · last reviewed 2026-07-23
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-23
Sources by quality tier
- 4
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for HistoSonics.In the press
Recent coverage mentioning HistoSonics from third-party publications. Automatically surfaced; not part of the verified registry record.
HistoSonics Secures $102M Series D Financing
$102M Series D led by Alpha Wave Ventures. FDA De Novo cleared Edison system for liver tumor histotripsy. $3.75B valuation.
New Financing Values HistoSonics at $3.75B
HistoSonics valued at $3.75B in latest financing with participation from Yosemite and other strategic investors.
Machine-readable surfaces
- Markdown mirror: /companies/histosonics.md
- RSS feed: /companies/histosonics/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/fffa2127-5d46-4965-b510-cf96161154f0
- Revision history: /companies/histosonics/history
- Data documentation: /data
- Query this programmatically: Deploy MCP